Publications by authors named "G Focaccia"
Article Synopsis
- The study assessed the effectiveness and side effects of docetaxel as a pre-surgery chemotherapy for patients with advanced cervical cancer, enrolling 38 untreated patients aged 25-66 over a span from 1998 to 2000.
- Results showed an overall objective response rate of 34%, with 1 patient achieving a complete response and 11 achieving partial responses, while some patients experienced no change or progressive disease.
- The treatment's primary toxicity included high rates of leukopenia, neutropenia, and myalgias, with significant side effects, but no severe hypersensitivity reactions were observed.
A phase II trial was performed to assess the efficacy and toxicity of a combination of ifosfamide (IFX), cisplatin (CDDP), and vinorelbine (VNB) as neoadjuvant chemotherapy (NAC) for untreated advanced cervical carcinoma (ACC). Between October 1995 and February 1998, 40 patients were entered in this study. Their median age was 43 years (range: 23-74 years).
View Article and Find Full Text PDFPurpose: To evaluate the efficacy and toxicity of vinorelbine (VNB) as single-agent neoadjuvant chemotherapy in advanced cervical carcinoma (ACC).
Patients And Methods: Between December 1993 and October 1995, 43 untreated patients with stages IIB to IVA squamous cell cervical cancer were entered onto this study. Forty-two patients are assessable for response and 43 for toxicity.
A phase II trial was performed to evaluate the efficacy and toxicity of a combination of cisplatin (CDDP) and ifosfamide (IFX) as neoadjuvant chemotherapy in advanced cervical carcinoma (ACC). Between August 1991 and September 1993, 57 untreated patients with stages IIB to IVA were entered into this study. Median age was 44 years (range, 25 to 74 years).
View Article and Find Full Text PDFBetween October 1986 and August 1988, 33 previously untreated patients with locally advanced cervical carcinoma were studied to evaluate the efficacy and toxicity of a neoadjuvant chemotherapy combination consisting of cisplatin 50 mg/m2 intravenously (IV) on day 1, vincristine 1.4 mg/m2 IV on day 1, and bleomycin 25 mg/m2 IV in a 6-hour infusion on days 1-3. Cycles were repeated every 10 days for a total of three cycles, after which definitive radiation therapy (external and intracavitary) was administered.
View Article and Find Full Text PDF